Omega Diagnostics Group PLC Update re AbC-19 Rapid Test
29 Dicembre 2020 - 8:01AM
RNS Non-Regulatory
TIDMODX
Omega Diagnostics Group PLC
29 December 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Update re AbC-19(TM) Rapid Test
Omega (AIM: ODX), the medical diagnostics company focused on
CD4, infectious diseases and food intolerance, notes today's update
from Abingdon Health plc (AIM: ABDX) regarding the AbC-19(TM) Rapid
Test and welcomes confirmation that they continue to work
constructively with the Medicines and Healthcare products
Regulatory Agency (MHRA) to try to enable approval for home use and
self-test of the AbC-19(TM) Rapid Test in the UK.
Abingdon have also confirmed that whilst the DHSC continues to
have first refusal for supplies of the AbC-19(TM) Rapid Test
through a Supply of Goods Contract that extends to 14 February
2021, the UK-RTC is liaising with customers and regulatory
authorities across a total of 27 international territories, to
allow future use of the product outside of the UK.
Colin King, CEO of Omega Diagnostics, said: "We welcome the
update from Abingdon Health this morning and we look forward to
being able to update investors on this approval process for
self-test use in due course. We remain confident that the
AbC-19(TM) Rapid Test has a potential global application and we are
delighted that the UK-RTC maintains constructive dialogue with
interested customers and regulatory authorities across the
world."
Contacts:
Omega Diagnostics Group PLC Tel: 01259 763 030
Bill Rhodes, Interim Non-Executive www.omegadiagnostics.com
Chairman
Colin King, Chief Executive
Kieron Harbinson, Group Finance
Director
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGZMZZMRZGGZZ
(END) Dow Jones Newswires
December 29, 2020 02:01 ET (07:01 GMT)
Grafico Azioni Omega Diagnostics (LSE:ODX)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Omega Diagnostics (LSE:ODX)
Storico
Da Apr 2023 a Apr 2024